ClinicalTrials.gg
CompletedNCT01802541Updated Mar 1, 2013

Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism

An interventional study of diacylglycerol oil and triacylglycerol oil in Insulin Sensitivity, Type 2 Diabetes and Cardiovascular Disease, sponsored by Zhejiang University. Completed. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-03-01.

Sponsored by Zhejiang University · Not applicable and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Diacylglycerol oil has been shown to lower postprandial and fasting serum triacylglycerol levels and reduce body fat. The investigators hypothesize that replacing dietary fat with diacylglycerol oil reduces excess body fat in type 2 diabetic patients and that diacylglycerol oil has a beneficial effect on cardiovascular risk factors in Chinese type 2 diabetic patients.

02

Conditions studied

  • Insulin Sensitivity
  • Type 2 Diabetes
  • Cardiovascular Disease

Keywords

  • diacylglycerol oil
  • insulin sensitivity
  • type 2 diabetes
  • cardiovascular disease
  • risk factors
03

In context

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

This study's planned enrollment of 127 is above the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.

Browse Insulin Resistance studies →

Lead sponsor

Zhejiang University is the lead sponsor of 357 studies on the registry; 167 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetic patients, blood sugar levels were stabilized between 7.0-10.0 mmol/L
  2. Male, aged 40 - 70 years old, Female, aged - 70 years old.
  3. Overweight/obese patients ( 25 - 40 kg/m2)
  4. Currently under diet therapy for diabetes mellitus
  5. Understands the procedures and willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Patients who unwilling to give
  2. Type 1 diabetic patients
  3. Familial hyperlipemia patients or blood triacylglycerol concentration > 400 mg/dl
  4. Patients with a history of cardiovascular disease and/or arteriosclerotic disease
  5. Patients with a history of cerebrovascular disease
  6. Patients with serious hepatic disease and/or renal disease
  7. Patients with
  8. Participation in another clinical study within 30 days prior to screening period.
  9. Has a condition the doctor in charge believes would interfere with evaluation of the subject, or may put subject at undue risk
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
127 participants (estimated)

Study arms

  • Experimental
    DAG oil

    Dietary Supplement: diacylglycerol oil

  • Placebo comparator
    TAG oil

    Dietary Supplement: triacylglycerol oil

Interventions

06

What researchers measure

Primary outcomes

  1. insulin resistance

    Time frame: 120 days

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01802541
Responsible party
Duo li (Professor, Zhejiang University) — Principal investigator
First posted
Mar 1, 2013
Primary completion
Feb 2006
Last update
Mar 1, 2013

Study contacts

Duo Li, Ph.D.
principal investigator

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacylglycerol oil

Start the discussion